Bexsero Dosing for Infants Starting Before 6 Months of Age

Critical Licensing Information

• The Centers for Disease Control and Prevention recommends that Bexsero is only FDA-licensed for persons aged 10-25 years in the United States 1, 2
• The FDA licenses Bexsero for use in persons aged 10-25 years, with specific dosing schedules for healthy adolescents and high-risk persons 1, 2

US-Licensed Dosing

• The Centers for Disease Control and Prevention recommends a 2-dose series of Bexsero at 0 and 6 months for healthy adolescents, and a 3-dose series at 0, 1-2, and 6 months for high-risk persons 3
• The Advisory Committee on Immunization Practices recommends that persons with complement deficiencies, asplenia, complement inhibitor use, microbiologists, or outbreak settings receive a 3-dose series of Bexsero at 0, 1-2, and 6 months 1, 2

Key Clinical Pitfalls

• The Centers for Disease Control and Prevention warns against confusing Bexsero with MenACWY vaccines, which are licensed for infant use starting at 2 months of age 4, 5
• The Centers for Disease Control and Prevention advises that the two MenB vaccines, Bexsero and Trumenba, are not interchangeable, and the same product must be used for all doses 1, 2